Handheld analyzer maker 908 Devices Inc's Q3 revenue beats estimates

908 Devices

10/11/2025 12:12

Overview

908 Devices Q3 revenue decreases 4% yr/yr but beats analyst expectations

Adjusted EBITDA loss improves 53% quarter over quarter

Net loss for Q3 misses analyst estimates

Outlook

Company expects full-year 2025 revenue between $54.0 mln and $56.0 mln

Company sees potential impact from U.S. Government shutdown on award timing

Result Drivers

FTIR DEMAND - Significant quarter-over-quarter increase in XplorIR placements and initial shipments of new VipIR device

REVENUE CHANNEL DIVERSITY - 47% of revenues from U.S. state and local channels, reducing reliance on federal contracts

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$14 mln
$13.60 mln (4 Analysts)
Q3 Net Income
Miss
-$15 mln
-$4.29 mln (3 Analysts)
Q3 Gross Profit
$7.40 mln
Q3 Operating Expenses
$23.70 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for 908 Devices Inc is $10.00, about 26.2% above its November 7 closing price of $7.38

Press Release: ID:nBwc4DXXma

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)